Skip to Main content Skip to Navigation
Journal articles

Safe and prolonged survival with Long-term exposure to Pomalidomide in Relapsed/Refractory Myeloma

Abstract : Background - The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had a prolonged progression-free survival (PFS) and subsequently overall survival (OS). We sought to analyze the characteristics of these patients and study the effect of long exposure to pomalidomide. Design - We separated the studied population into two groups: 3 months to 1 year (<1 year) and more than 1 year (≥1 year) of treatment with pomalidomide and dexamethasone based on clinical judgment and historical control studies. We then analyzed the characteristics of patients according to duration of treatment. Results - The overall response rate (ORR) for the <1-year group was 43%, the median PFS 4.6 months [95% confidence interval (95% CI) 3.8-6.4] with only 6% at 12 months, and the median OS was 15 months (11.7-20.3) and 40% at 18 months. For the ≥1-year group, the response rate and survival were strikingly different, ORR at 83%, median PFS 20.7 months (14.7-35.4), median OS not reached, and 91% at 18 months. Conclusion - Pomalidomide and dexamethasone favored prolonged and safe exposure to treatment in 40% of heavily treated and end-stage RRMM, a paradigm shift in the natural history of RRMM characterized with a succession of shorter disease-free intervals and ultimately shorter survival. Although an optimization of pomalidomide-dexamethasone regimen is warranted in advanced RRMM, we claim that pomalidomide has proven once more to change the natural history of myeloma in this series, which should be confirmed in a larger study.
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01263111
Contributor : Laurent Jonchère <>
Submitted on : Monday, September 19, 2016 - 2:47:10 PM
Last modification on : Wednesday, October 14, 2020 - 4:15:00 AM

File

Safe and prolonged survival wi...
Files produced by the author(s)

Identifiers

Citation

G. Fouquet, B. Pégourié, M. Macro, M. O. Petillon, L. Karlin, et al.. Safe and prolonged survival with Long-term exposure to Pomalidomide in Relapsed/Refractory Myeloma. Annals of Oncology, Elsevier, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩. ⟨hal-01263111⟩

Share

Metrics

Record views

1156

Files downloads

890